Cdt1 interactions in the licensing process: a model for dynamic spatiotemporal control of licensing
Related Experiment Video
Updated: Jul 14, 2026

Real-Time Proxy-Control of Re-Parameterized Peripheral Signals using a Close-Loop Interface
Published on: May 8, 2021
Georgia Xouri1, Maria Dimaki, Philippe I H Bastiaens
1Laboratory of General Biology, School of Medicine, University of Patras, Patras, Greece.
Abstract:
Within each cell cycle, a cell must ensure that the processes of selection of replication origins (licensing) and initiation of DNA replication are well coordinated to prevent reinitiation of DNA replication from the same DNA segment during the same cell cycle. This is achieved by restricting the licensing process to G1 phase when the prereplicative complexes (preRCs) are assembled onto the origin DNA, while DNA replication is initiated only during S phase when de novo preRC assembly is blocked. Cdt1 is an important member of the preRC complex and its tight regulation through ubiquitin-dependent proteolysis and binding to its inhibitor Geminin ensure that Cdt1 will only be present in G1 phase, preventing relicensing of replication origins. We have recently reported that Cdt1 associates with chromatin in a dynamic way and recruits its inhibitor Geminin onto chromatin in vivo. Here we discuss how these dynamic Cdt1-chromatin interactions and the local recruitment of Geminin onto origins of replication by Cdt1 may provide a tight control of the licensing process in time and in space.
Related Concept Videos
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
Properties of DTFT I
The linearity property of DTFTs is fundamental. If two discrete-time signals are multiplied by constants a and b respectively, and then combined to...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
